Recent advances in myeloma treatment

Transfusion and Apheresis Science

Volumn 44, Issue 2, 2011, Pages 223-229

  Schots, R ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Multiple myeloma; Myeloma treatment

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PLACEBO; POMALIDOMIDE; PREDNISONE; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CHOLELITHIASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSESTHESIA; FATIGUE; HERPES ZOSTER; HUMAN; INFECTION; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NAUSEA; NEURALGIA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POLYNEUROPATHY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; SENSORY NEUROPATHY; SOMNOLENCE; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WEAKNESS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MEDICAL ONCOLOGY; MELPHALAN; MULTIPLE MYELOMA; OLIGOPEPTIDES; PREDNISONE; PYRAZINES; QUALITY OF LIFE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 79952627778     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2011.01.018     Document Type: Article

References (52)

1. Podar K., Chauhan D., Anderson K.C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009, 23:10-24.
2. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
3. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
4. Hulin C., Facon T., Rodon P., Pegourie B., Benboubker L., Doyen C., et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009, 27:3664-3670.
5. Wijermans P., Schaafsma M., Termorshuizen F., Ammerlaan R., Wittebol S., Sinnige H., et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol 2010, 28:3160-3166.
6. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
7. Mateos M.V., Oriol A., Martinez J., Cibeira M.T., Gutierrez N.C., Terol M.J., et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65years. ASH Annu Meet Abstr 2009, 114:3.
8. Palumbo A., Bringhen S., Rossi D., Ria R., Offidani M., Patriarca F., et al. Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients. Blood 2009, 114:58.
9. Dimopoulos M.A., Richardson P.G., Schlag R., Khuageva N.K., Shpilberg O., Kastritis E., et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009.
10. Palumbo A., Dimopoulos M.A., Delforge M., Kropff M., Foa R., Yu Z.A., et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. ASH Annu Meet Abstr 2009, 114:613.
11. Morgan G.J., Davies F.E., Gregory W.M., Bell S.E., Szubert A.J., Cocks K., et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. ASH Ann Meet Abstr 2009, 114:352.
12. Rajkumar S.V., Jacobus S., Callander N.S., Fonseca R., Vesole D.H., Williams M.E., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2009.
13. Lokhorst H.M., van der H.B., Zweegman S., Vellenga E., Croockewit S., van Oers M.H., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
14. Harousseau J.L., Avet-Loiseau H., Facon T., Attal M., Doyen C., Hulin C., et al. Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexamethasone (VTD) as induction treatment prior to autologous stem-cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annu Meet Abstr 2009, 114:354.
15. Cavo M., Tacchetti P., Patriarca F., Petrucci M.T., Pantani L., Galli M.A., et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. ASH Annu Meet Abstr 2009, 114:351.
16. Sonneveld P., van der Holt B., Schmidt-Wolf I.G.H., Bertsch U., Jarari Le., Salwender H.J., et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). ASH Annu Meet Abstr 2008, 112:653.
17. Dispenzieri A., Rajkumar S.V., Gertz M.A., Fonseca R., Lacy M.Q., Bergsagel P.L., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323-341.
18. Attal M., Harousseau J.L., Leyvraz S., Doyen C., Hulin C., Benboubker L., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289-3294.
19. Spencer A., Prince H.M., Roberts A.W., Prosser I.W., Bradstock K.F., Coyle L., et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009, 27:1788-1793.
20. Attal M., Harousseau J.L., Marit G., Caillot D., Stoppa A.M., Benboubker L., et al. Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the intergroup francophone du myeloma (IFM 2005 02). Blood 2009, 114:220-221.
21. Garcia-Sanz R., Gonzalez-Porras J.R., Hernandez J.M., Polo-Zarzuela M., Sureda A., Barrenetxea C., et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004, 18:856-863.
22. Kyriakou C., Thomson K., D'Sa S., Flory A., Hanslip J., Goldstone A.H., et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005, 129:763-770.
23. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
24. Jagannath S., Richardson P.G., Barlogie B., Berenson J.R., Singhal S., Irwin D., et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91:929-934.
25. Kropff M., Bisping G., Schuck E., Liebisch P., Lang N., Hentrich M., et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007, 138:330-337.
26. Davies F.E., Wu P., Jenner M., Srikanth M., Saso R., Morgan G.J. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007, 92:1149-1150.
27. Orlowski R.Z., Nagler A., Sonneveld P., Blade J., Hajek R., Spencer A., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
28. Pineda-Roman M., Zangari M., van Rhee F., Anaissie E., Szymonifka J., Hoering A., et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008, 22:1419-1427.
29. Palumbo A., Ambrosini M.T., Benevolo G., Pregno P., Pescosta N., Callea V., et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007, 109:2767-2772.
30. Blade J., Sonneveld P., San Miguel J.F., Sutherland H.J., Hajek R., Nagler A., et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008, 8:352-355.
31. Roussou M., Kastritis E., Migkou M., Psimenou E., Grapsa I., Matsouka C., et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008, 49:890-895.
32. San Miguel J.F., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
33. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
34. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
35. Reece D., Song K.W., Fu T., Roland B., Chang H., Horsman D.E., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 12.
36. Garban F., Attal M., Michallet M., Hulin C., Bourhis J.H., Yakoub-Agha I., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
37. Bruno B., Rotta M., Patriarca F., Mordini N., Allione B., Carnevale-Schianca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
38. Rosinol L., Perez-Simon J.A., Sureda A., de la R.J., de Arriba F., Lahuerta J.J., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
39. Bruno B., Rotta M., Patriarca F., Mattei D., Allione B., Carnevale-Schianca F., et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009, 113:3375-3382.
40. Schey S.A., Morgan G.J., Ramasamy K., Hazel B., Ladon D., Corderoy S., et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol 2010, 150:326-333.
41. Palumbo A., Larocca A., Falco P., Sanpaolo G., Falcone A.P., Federico V., et al. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia 2010, 24:1037-1042.
42. Kim Y.K., Sohn S.K., Lee J.H., Yang D.H., Moon J.H., Ahn J.S., et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 2010, 89:475-482.
43. Richardson P.G., Weller E., Lonial S., Jakubowiak A.J., Jagannath S., Raje N.S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
44. Kropff M., Liebisch P., Knop S., Weisel K., Wand H., Gann C.N., et al. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann Hematol 2009, 88:1125-1130.
45. Bensinger W.I., Jagannath S., Vescio R., Camacho E., Wolf J., Irwin D., et al. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br J Haematol 2010, 148:562-568.
46. Lacy M.Q., Hayman S.R., Gertz M.A., Dispenzieri A., Buadi F., Kumar S., et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27:5008-5014.
47. Siegel D., Wang L.H., Orlowski R.Z., Kaufman J.L., Stewart A.K., Kukreti V., et al. PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood 2009, 114:128.
48. Wang L.H., Siege D., Kaufman J.L., Stewart A.K., Jakubowiak A.J., Alsina M., et al. Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). Blood 2009, 114:127-128.
49. Vij R., Wang L.H., Orlowski R.Z., Stewart A.K., Jagannath S., Lonial S., et al. Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects. Blood 2009, 114:178-179.
50. Ocio E.M., Vilanova D., Atadja P., Maiso P., Crusoe E., Fernandez-Lazaro D., et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematol - Hematol J 2010, 95:794-803.
51. Ghobrial I.M., Vij R., Munshi N.C., Schlossman R.L., Laubach J., Campagnaro E.L., et al. Phase II trial of weekly bortezomib in combination with CCI-779 (temsirolimus) in relapsed or relapsed/refractory multiple myeloma. Blood 2009, 114:311-312.
52. Lonial S., Vij R., Harousseau J.L., Facon T., Kaufman J., Mazumder A., et al. Phase 1/2 study of elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory multiple myeloma: interim results. Blood 2009, 114:179-180.